Sign in Subscribe
Stock exchanges

Revolution Medicines, Inc. Announces 2025 Annual Meeting Results

Strategic Insights

— 1 min read

Revolution Medicines, Inc. recently held its 2025 annual meeting of stockholders on June 26, 2025, where attendees voted on three proposals. The meeting saw significant turnout, with 147,380,169 shares cast for Proposal 1, which involved the election of four Class II directors. The four nominees elected were Frank K. Clyburn, Jr., Sandra J. Horning, M.D., Sushil Patel, Ph.D., and Thilo Schroeder, Ph.D. The election of these directors ensures that the company's leadership will continue to guide the organization in its mission to develop innovative treatments for diseases.

Another key proposal, Proposal 2, involved the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposal passed with 157,875,830 votes in favor. This decision will provide continuity in the company's financial auditing processes, ensuring that financial statements are accurate and reliable.

The final proposal, Proposal 3, addressed the compensation of the company's named executive officers. On a non-binding advisory basis, the proposal was approved with 145,265,825 votes in favor. This outcome demonstrates the support of stockholders for the company's executive compensation policies.

Key Takeaways:

  • The company's stockholders elected four Class II directors to hold office until the 2028 annual meeting: Frank K. Clyburn, Jr., Sandra J. Horning, M.D., Sushil Patel, Ph.D., and Thilo Schroeder, Ph.D.
  • PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 157,875,830 votes in favor.
  • The proposal on Executive Compensation was approved with 145,265,825 votes in favor.

Statistics:

  • 186,261,742 shares of the company's common stock were outstanding and entitled to vote at the meeting.
  • 147,380,169 shares were cast for Proposal 1.
  • 157,875,830 votes were cast in favor of Proposal 2.
  • 145,265,825 votes were cast in favor of Proposal 3.

Sources:

  • Form 8-K (Current Report) filed by Revolution Medicines, Inc. with the SEC on June 27, 2025.
  • Definitive Proxy Statement on Schedule 14A filed by Revolution Medicines, Inc. with the SEC on April 29, 2025.

Read more